Details of the Drug Reposition

General Information of This Drug (ID: DM9LFYN)

Drug Name
Tesetaxel   DM9LFYN
Synonyms
Tesetaxel; DJ-927; 333754-36-2; UNII-UG97LO5M8Y; UG97LO5M8Y; Tesetaxel [INN]; DJ927; DJ 927; CHEMBL2107787; SCHEMBL12060837; DB12019; Z-3104; (2AS,2BR,3S,4S,6S,8AR,10R,11AS,11BR,13AR)-2A-ACETOXY-6-(((2R,3S)-3-((TERT-BUTOXYCARBONYL)AMINO)-3-(3-FLUOROPYRIDIN-2-YL)-2-HYDROXYPROPANOYL)OXY)-10-((DIMETHYLAMINO)METHYL)-4-HYDROXY-7,11B,14,14-TETRAMETHYL-2A,2B,3,4,5,6,8A,11A,11B,12,13,13A-DODECAHYDRO-2H-4,8-METHANOOXETO[3'',2'':3',4']BENZO[1',2':3,4]CYCLODECA[1,2-D][1,3]DIOXOL-3-YL BENZOATE
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Breast cancer DIS7DPX1 2C60-2C65 Phase 3 [1]
------------------------------------------------------------------------------------
4 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Gastric adenocarcinoma DISWWLTC 2B72 Phase 2 [2]
Melanoma DIS1RRCY 2C30 Phase 2 [2]
Prostate cancer DISF190Y 2C82.0 Phase 2 [2]
Bladder cancer DISUHNM0 2C94 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01221870) Tesetaxel as First-line Therapy for Metastatic Breast Cancer. U.S. National Institutes of Health.